Receptor and non-receptor mediated uptake of chylomicron remnants by the liver.

Atherosclerosis

Cardiovascular Research Institute, University of California, San Francisco 94143-0130, USA.

Published: December 1998

The uptake of chylomicron remnants by rodent liver is mediated by proteins residing on the microvillous surface of hepatocytes and occurs in two steps. First, initial removal of the remnants from the blood occurs through binding to the low density lipoprotein (LDL) receptor via apo E and to hepatic lipase via polar lipids and proteins on the remnant surface. Second, chylomicron remnants are taken up into the cell mainly by the LDL receptor and follow the classical receptor-mediated pathway of endocytosis. The LDL receptor-related protein (LRP), which binds weakly to chylomicron remnants via apo E, does not appear to have a significant role in the initial removal process. The remnant particles can, however, be enriched with proteoglycan-bound apo E present on hepatocytic microvilli, which increases their affinity for LRP to the extent that they are subject to endocytosis by this receptor, particularly when the LDL receptor is deficient or down-regulated. Hepatic lipase can also mediate binding of remnants to LRP, for which it has high affinity. Lipolysis of remnant lipids by hepatic lipase may promote but is not required for interaction of remnants with the endocytic receptors. Proteoglycan-bound hepatic lipase may also mediate endocytosis of chylomicron remnants independent of apo E, so that hepatic catabolism of these particles is not completely dependent upon this apoprotein. Available data from experiments in vivo thus indicate redundancy of both steps of hepatic uptake of chylomicron remnants, consistent with the centrality of this process in nutrient delivery.

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0021-9150(98)00211-1DOI Listing

Publication Analysis

Top Keywords

chylomicron remnants
24
hepatic lipase
16
uptake chylomicron
12
ldl receptor
12
remnants
9
initial removal
8
apo hepatic
8
lipase mediate
8
chylomicron
6
hepatic
6

Similar Publications

Over 50% of patients who take statins are still at risk of developing atherosclerotic cardiovascular disease (ASCVD) and do not achieve their goal LDL-C levels. This residual risk is largely dependent on triglyceride-rich lipoproteins (TRL) and their remnants. In essence, remnant cholesterol-rich chylomicron (CM) and very-low-density lipoprotein (VLDL) particles play a role in atherogenesis.

View Article and Find Full Text PDF

Discordance Analysis of VLDL-C and ApoB in UK Biobank and Framingham Study: A Prospective Observational Study.

Arterioscler Thromb Vasc Biol

October 2024

Department of Medicine, Mike and Valeria Rosenbloom Centre for Cardiovascular Prevention, McGill University Health Centre, Montreal, Quebec, Canada (S.B., K.M.P., J.C., L.D., G.T., A.D.S.).

Background: Recent observational and Mendelian randomization analyses have reported significant effects of VLDL-C (very-low density lipoprotein cholesterol) on risk that is independent of ApoB (apolipoprotein B). We aim to determine the independent association of VLDL-C and ApoB with the risk of new onset cardiovascular events in the UK Biobank and Framingham Heart Study cohorts.

Methods: We included 294 289 UK Biobank participants with a median age of 56 years, 42% men, and 2865 Framingham Heart Study participants (median age, 53 years; 47% men).

View Article and Find Full Text PDF
Article Synopsis
  • Postprandial hypertriglyceridemia (PHTG) is linked to coronary heart disease due to the harmful buildup of chylomicron remnants (CM-Rs) and VLDL remnants (VLDL-Rs), with CM-Rs being less understood.
  • This study successfully isolated CM-Rs and VLDL-Rs from blood samples taken 3 hours after consuming high-fat meals using specialized antibodies and advanced proteomic analysis.
  • Key findings include the identification of 42 associated proteins—11 of which are newly discovered—highlighting specific proteins in CM-Rs that may contribute to their atherogenic nature, thus providing insights into their potential health risks.
View Article and Find Full Text PDF

The chylomicron saga: time to focus on postprandial metabolism.

Front Endocrinol (Lausanne)

February 2024

Glycation, Oxidation and Disease Laboratory, Department of Research, Touro University California, Vallejo, CA, United States.

Since statins have had such tremendous therapeutic success over the last three decades, the field of atherosclerosis has become somewhat LDL-centric, dismissing the relevance of triglycerides (TG), particularly chylomicrons, in atherogenesis. Nonetheless, 50% of patients who take statins are at risk of developing atherosclerotic cardiovascular disease (ASCVD) and are unable to achieve their goal LDL-C levels. This residual risk is mediated, in part by triglyceride rich lipoproteins (TRL) and their remnants.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!